ARQT

Arcutis Biotherapeutics develops and commercializes dermatology treatments addressing significant unmet medical needs in immune-mediated inflammatory skin diseases. Headquartered in Westlake Village, California, the company focuses on topical therapies for plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and other prevalent skin conditions affecting millions of patients who experience inadequate efficacy or tolerability issues with existing treatments. Arcutis's lead commercial product, ZORYVE (roflumilast) cream 0.3%, received FDA approval for plaque psoriasis in July 2022 and atopic dermatitis in July 2023, representing the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved for these indications. The company markets ZORYVE through a specialized dermatology sales force targeting dermatologists and healthcare providers treating inflammatory skin diseases, generating revenue through prescription fulfillment covered by commercial insurance and Medicare plans. Arcutis's pipeline includes additional formulations and indications for roflumilast including a foam formulation for scalp psoriasis and seborrheic dermatitis currently in clinical development. The company completed its initial public offering in February 2020 raising capital for clinical trials and commercial launch preparations. Arcutis employs approximately 350 people including sales representatives, medical affairs professionals, and research personnel supporting clinical development and commercial expansion across dermatology markets.